Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516407 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Electronic (PDF)Add to Basket
Electronic (Online Access)Add to Basket
Hard CopyAdd to Basket
Live Chat Live Help Software for Website

Covidien Company Intelligence Report

Espicom Business Intelligence Ltd, Nov 2011, Pages: 58


  Description  
   Table of Contents   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

Covidien offers an extensive healthcare product line that spans medical devices, medical supplies and pharmaceuticals. Since 1994, the company has significantly expanded its product portfolio, primarily through key acquisitions, such as Kendall, Mallinkrodt (and its subsidiaries, Nellcor and Puritan Bennett) and US Surgical (including its subsidiary, Valleylab). As of September 2011, Covidien employed approximately 41,300 people in 65 countries worldwide. It had 48 manufacturing facilities in 16 countries and its products were sold in over 140 countries.

Covidien Ltd (formerly Tyco Healthcare) was formed on 29th June 2007 after Tyco International, its former parent company, was separated into three independent, publicly-traded companies. Tyco International transferred the equity of the entities that held all of the assets and liabilities of its healthcare business to Covidien and distributed all of its shares of Covidien to its shareholders. The shares of Covidien began trading on the New York and Bermuda stock exchanges on 2nd July 2007.

In 2009, Covidien moved its principal executive office from Bermuda to Dublin, Ireland, and ceased trading its shares on the Bermuda stock exchange. The company's corporate offices are located in Mansfield, Massachusetts, US.

Since 2008, Covidien has sold several businesses consistent with its strategy to streamline its portfolio and re-allocate resources to faster-growing, higher-margin operations. These have included the sale of its Retail Products, European Incontinence, Speciality Chemicals, Sleep Diagnostics, and Oxygen and Sleep Therapy assets.

Following on from the key acquisitions mentioned above, which included a number of globally-recognised brands, Covidien has targeted its investments at businesses that complement its existing portfolio or enable it to enter adjacent markets, as well as obtain licences to access new technologies. The purchases of Aspect Medical, VNUS Medical Technologies, ev3, Somanetics and Barrx Medical are typical examples of this.

In 2009, Covidien made a number of segment reporting changes to align external reporting with changes to its internal reporting structure. The company combined its Pharmaceutical Products and Imaging Solutions segments into a single operating segment called Pharmaceuticals. In addition, it reclassified the SharpSafety and Clinical Care product lines in the US and Europe from its Medical Devices segment to the Medical Supplies segment. The company also reclassified several hernia mechanical devices from its Endomechanical Instruments product line to its Soft Tissue Repair product line, both within the Medical Devices segment, and made several other less significant transfers between product lines and segments.

As a result of these changes, Covidien now manages and operates its business through three segments:

- Medical Devices: IT includes the development, manufacture and sale of endomechanical instruments, soft tissue repair products, energy devices, oximetry and monitoring products, airway and ventilation products, products used in vascular therapies and other medical products;

- Medical Supplies: it includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer (OEM) products;

- Pharmaceuticals - includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals.

In the fiscal year (FY) ended September 2011, Covidien reported net income of US$1.87 billion on revenues of US$11.57 billion. Approximately 55% of the company's net sales are generated in the US and 45% are generated outside of the US. This report primarily focuses on the Medical Devices and Medical Supplies segments of Covidien's business.

ABOUT THIS REPORT

This company report provides:

Overview
- Key contact information
- Introduction to the company and its current activities
- Summary of its financial performance
- Who are the company's major competitors?
- Key recent events in an “at a glance” format

Financial Review
- Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
- Table providing in-depth five-year financial analysis
- Employee data, including breakdown by company division and geographic location

Strategic Focus
- Investigates the company's aims and its areas of focus

Products
- Core product areas, key brands, product approvals and launches Research and Development
- How much has been invested in R&D?
- Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
- Identifying the company's manufacturing locations
- Sales and marketing facilities

Agreements
- With whom has the company reached agreements and what do they involve?
- Key contracts awarded

Mergers, Acquisitions, Minority Investments and Divestments

Litigation

Key Corporate Events

ABOUT MEDICAL DEVICE COMPANIES ANALYSIS (MCDA)

The report was produced as part of Medical Device Companies Analysis (MDCA).



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds